Printer Friendly

Decreased expression of chromodomain helicase DNA-binding protein 9 is a novel independent prognostic biomarker for colorectal cancer.

Introduction

Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. It has become the third leading cause of cancer-related death worldwide (1). In recent years, with the rapid development of the Chinese economy and change of diet, CRC has become one of the malignant tumors with the fastest rising incidence in China (2,3). Although it has become routine to screen for the disease and new technologies are being developed, the prevention, treatment, and prognosis of CRC remain a significant problem in the global public health field. Therefore, a better understanding of the molecular mechanisms involved in the progression of CRC is crucial to explore novel therapeutic targets for CRC treatment.

The chromodomain helicase DNA-binding proteins (CHDs) are a family of nine members named CHD 1-9, which act as regulators of chromatin remodeling process and gene expression in humans. Chromatin remodeling is the dynamic modification of chromatin architecture to allow access of condensed genomic DNA to the regulatory transcription machinery proteins, playing a critical role in regulating gene expression during the developmental period. All CHD proteins contain two basal tandem chromo domains and different additional domains. Thus, the CHD family could be divided into three sub-families according to the additional domains and features: CHD 1-2, CHD 3-5, and CHD 6-9 (4,5). There is emerging evidence suggesting that CHDs might contribute to a broad spectrum of human diseases and cancers, including lymphoma, liver cancer, colorectal cancer, stomach cancer, etc (6-9). The third sub-family of CHD enzymes are orthologs of the Drosophila Kismet enzyme and are characterized by the Brahma and Kismet domains at C termini. The mutant of CHD 7 and 8 could lead to the distinct disease states of CHARGE syndrome (10) and autism spectrum disorders (11). However, to date, few studies on the CHD 9 protein in human disease have been reported.

Previous studies have shown that CHD 9 has a certain mutation rate in high-level microsatellite instability (MSI-H) CRC, but neither its role in CRC nor its effect on prognosis has yet been reported (5). Approximately 12-15% CRC have deficient DNA mismatch repair, which is characterized in the tumor by MSI (12). Therefore, it is of great importance to study the specific mechanism of CHD 9 in CRC and its effect on the prognosis of CRC. Here, we evaluated CHD 9 expression in CRC in Chinese patients. To our knowledge, this is the first study to assess the prognostic value of CHD 9 in CRC.

Material and Methods

A total of 87 patients with CRC (44 females, 42 males, 1 lost information) who had undergone surgical procedures at Yijishan Hospital of Wannan Medical College between July 2006 and May 2007 were enrolled in the study. The patients' tissue microarray contained well-documented clinical-pathological information, including patients' gender, age, tumor size, tumor differentiation, stage, N stage, distant metastasis, and clinical stage (Table 1). Patients ranged in age from 24 to 90 (means [+ or -] SD, 69.51 [+ or -] 11.01). Mean tumor size was 5.7 cm (range 1.5-15.0).

The patients' CRC tissue microarray (HCol-Adel180sur-06) was made by Shanghai Outdo Biotech Co., Ltd. (China). The CRC microarray was constructed by formalin-fixed tissue samples embedded in paraffin from 87 patients. The typical pathological sites on HE slices were labeled by pathologists, then drilled on the blank recipient paraffin (diameter was 1.5 mm) using tissue microarray instrument. All of the 87 samples with their adjacent para-carcinoma tissues were collected 1.5 cm away from the cancer tissue.

The follow-up time of CRC patients was August 2015, ranging from 87 to 97 months. The result of statistical analysis showed that during the follow-up time, 56 of the 87 patients died of CRC, and the other 31 patients were still alive, with the median follow-up time of about 92 months. All patients were diagnosed as CRC and received no treatment before surgery.

This study was approved by the Ethics Committee of the Yijishan Hospital of Wannan Medical College, and informed consent was obtained from all the participants.

Immunohistochemistry

Two-step immunohistochemistry assay was used in this study. Tissue sections were treated with EDTA buffer under high pressure at high temperature to retrieve antigen. Then, sections were incubated with primary antibody named anti-CHD9 (1:3000, 13402-1-AP, Proteintech, USA) at 4[degrees]C overnight. Sections were then washed with PBS after incubating with secondary antibody (HRP-labeled anti-rabbit antibody; DAKO, Denmark). Samples were visualized using diaminobenzidine system and hematoxylin re-dying, and analyzed under microscope (OLYMPUS CX41, Japan). Three random high-magnification fields of each specimen were chosen under optical microscope and more than 300 cells were selected for the evaluation. The CHD 9 expression was scored and grouped by positive staining rate and intensity. The positive staining rate was defined according to the proportion of stained cancer cells: "Negative" is 0, " 1-25%" is 1, "26-50%" is 2, "51-75%" is 3, "76-100%" is 4. The score for staining intensity was defined as follows: "Negative" is 0, " 1 +" is 1, "2 + " is 2, "3 + " is 3. Thus, patients were divided into low expression (p8) and high expression (>8) groups according to the scores after multiplying "positive staining rate score" by the "staining intensity score".

Statistical analysis

Student's t-test or one-way ANOVA was used to assess the association between CHD 9 expression and various clinic-pathological parameters and molecular markers. Spearman's correlation analysis was used to calculate the relationship between the CHD9 expression and the several mismatch repair genes including MLH1, MSH2, MSH6, and PMS2. The survival rate was calculated with the Kaplan-Meier method and differences were evaluated using the log-rank test. Finally, statistically significant variables in univariate analysis were included in COX multivariate regression survival analysis. In all tests, two-sided P values <0.05 were considered statistically significant.

Results

Representative immunohistochemistry images are shown in Figure 1. The CHD 9 expression was upregulated in 81.5% of the cases, while 7.4% of the cases showed decreased expression. CHD 9 expression was not altered in the remaining 11.1%. Spearman's correlation analysis showed that the expression of CHD 9 was neither correlated with age, gender, tumor size, nor the clinical classification or pathological grading (all P>0.05). The results are shown in Table 1.

Spearman's correlation analysis was used to assess the relationships between CHD 9 expression and mismatch repair genes including MLH1, MSH2, MSH6, and PMS2. CHD9 expression was positively correlated with MSH2 ([r.sub.s]=0.232, P=0.036) (Table 2).

Kaplan-Meier method and the log-rank test showed that CRC patients with high expression of CHD 9 had a significantly better prognosis than those with low level (54.5 vs 32.1%, P=0.034). The results are shown in Figure 2.

COX survival analysis showed that CHD 9 expression was an independent predictor for CRC, with a hazard ratio (HR) of 0.503 (P=0.028). The results are reported in Table 3.

Discussion

CHD protein family is extremely important in regulating gene expression and chromosome structure modification. CHD protein expression is associated with many diseases, such as lymphoma, liver cancer, colon cancer, gastric cancer, etc (4,6,13). CHD 9 has a certain mutation rate in the CRC of MSI-H, but its specific mechanism in CRC and the effects on prognosis have not yet been reported (5).

Based on previous research, MSI refers to repeated DNA nucleotide units in microsatellites, which arises in tumors when the function of mismatch repair is decreased by the inactivation of any one of the four mismatched repair genes: MLH1, MSH2, MSH6, and PMS2 (14). About 12-15% CRC have deficient DNA mismatch repair and the MSI-H phenotype, although the majority of colorectal cancers develop via a chromosomal instability pathway and follow the classical adenoma-carcinoma sequence of tumor progression (10,15-18).

The present study demonstrated that CHD 9 expression was positively correlated with MSH2. Previous studies have shown that DNA damage repair mechanism is a critical pathway to ensure genome stability. CHDs are correlated with DNA damage repair: CHD 4 acts as a key regulator of homologous recombination repair through binding to BRIT1 (19). CHD 2, 3, 5, and 6 are also associated with DNA repair, the maintenance of genomic stability and/or cancer prevention (20,21). Thus, we assumed that CHD 9 might inhibit the development of colorectal cancer by participating in the DNA repair process. Our study assessed for the first time the relationship between CHD 9 remodeling protein and CRC progression. The results showed that patients with high CHD 9 expression had better prognosis and that CHD 9 expression was an independent predictor for colorectal cancer. Our findings indicated that the CHD 9 is a putative tumor suppressor gene and a new potential prognostic biomarker in CRC.

In conclusion, our research showed a correlation between CHD 9 expression and CRC prognosis, as well as the potential pathways of DNA mismatch repair process. Further study, such as examining the effect of CHD 9 expression on cellular function by knocking out or expressing CHD 9 genes in CRC cell lines, will be done to explore the tumor suppressor mechanism of CHD9.

http://dx.doi.org/10.1590/1414-431X20187588

Acknowledgements

This study was supported by funding from the Anhui Provincial University Science Research Project (grant No. KJ2016A733).

References

(1.) Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117, doi: 10.3322/ caac.21220.

(2.) Irving AA, Yoshimi K, Hart ML, Parker T, Clipson L, Ford MR, et al. The utility of Apc-mutant rats in modeling human colon cancer. Dis Model Mech 2014; 7: 1215-1225, doi: 10.1242/ dmm.016980.

(3.) Irving AA, Plum LA, Blaser WJ, Ford MR, Weng C, Clipson L, et al. Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer. J Nutr 2015; 145: 291-298, doi: 10.3945/jn.114. 204396.

(4.) Salomon-Kent R, Marom R, John S, Dundr M, Schiltz LR, Gutierrez J, et al. New Face for Chromatin-Related Mesenchymal Modulator: n-CHD9 Localizes to Nucleoli and Interacts With Ribosomal Genes. J Cell Physiol 2015; 230: 2270-2280, doi: 10.1002/jcp.24960.

(5.) Shur I, Benayahu D. Characterization and functional analysis of CReMM, a novel chromodomain helicase DNA-binding protein. J Mol Biol 2005; 352: 646-655, doi: 10.1016/j.jmb. 2005.06.049.

(6.) Lin YW, Yan MD, Shih YL, Hsieh CB. The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. Eur J Cancer 2009; 45: 2041-2049, doi: 10.1016/j.ejca.2009.04.012.

(7.) Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 2011; 58: 660-668, doi: 10.1111/j.1365-2559.2011.03819.x.

(8.) Potts RC, Zhang P, Wurster AL, Precht P, Mughal MR, Wood WH 3rd, et al. CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS One 2011; 6: e24515, doi: 10.1371/ journal.pone.0024515.

(9.) de Dieuleveult M, Yen K, Hmitou I, Depaux A, Boussouar F, Bou Dargham D, et al. Genome-wide nucleosome specificity and function of chromatin remodellers in ES cells. Nature 2016; 530: 113-116, doi: 10.1038/nature16505.

(10.) Basson MA, van Ravenswaaij-Arts C. Functional insights into chromatin remodelling from studies on CHARGE syndrome. Trends Genet 2015; 31: 600-611, doi: 10.1016/j.tig.2015.05.009.

(11.) De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515: 209-215, doi: 10.1038/ nature13772.

(12.) Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol 2015; 16: 30, doi: 10.1007/ s11864-015-0348-2.

(13.) Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 2015; 163: 712-723, doi: 10.1016/j.cell.2015.09.053.

(14.) Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017; 37: 785-792, doi: 10.3892/or.2016.5323.

(15.) Sinicrope FA. The role of microsatellite instability testing in management of colorectal cancer. Clin Adv Hematol Oncol 2016; 14: 476-479.

(16.) Arnold A, Kloor M, Jansen L, Chang-Claude J, Brenner H, von Winterfeld M, et al. The association between microsatellite instability and lymph node count in colorectal cancer. VirchowsArch 2017; 471: 57-64, doi: 10.1007/s00428-0172150-y.

(17.) Carethers JM. Microsatellite Instability Pathway and EMAST in Colorectal Cancer. Curr Colorectal Cancer Rep 2017; 13: 73-80, doi: 10.1007/s11888-017-0352-y.

(18.) Kloor M, Staffa L, Ahadova A, von Knebel Doeberitz M. Clinical significance of microsatellite instability in colorectal cancer. Langenbecks Arch Surg 2014; 399: 23-31, doi: 10.1007/ s00423-013-1112-3.

(19.) Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, et al. Chromodomain helicase DNA-binding protein 4 (CHD 4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 2012; 287: 67646772, doi: 10.1074/jbc.M111.287037.

(20.) Stanley FK, Moore S, Goodarzi AA. CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res 2013; 750: 31-44, doi: 10.1016/j.mrfmmm.2013.07.008.

(21.) Seldon CS, Colbert LE, Hall WA, Fisher SB, Yu DS, Landry JC. Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World J Gastrointest Oncol 2016; 8: 358-365, doi: 10.4251/wjgo.v8.i4.358.

Li Xu [1], Hui Peng [2], Xiao-Xu Huang [1], Ya-Bin Xia [1], Kai-Feng Hu [1] and Zheng-Ming Zhang [1]

[1] Department of General Surgery, the First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

[2] Administration Office of Hospital Admission and Discharge, the First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

Correspondence: Li Xu: <yjsxuli@yeah.net>

Received March 15, 2018 | Accepted May 15, 2018

Caption: Figure 1. Representative immunohistochemistry images of CHD 9 expression in colorectal cancer tissues and para- carcinoma tissues: A, high CHD 9 expression in tumor; B, low CHD 9 expression in tumor; C, high CHD 9 expression in adjacent tissues; D, low CHD 9 expression in adjacent tissues (Magnification: x 200; bar: 100 [micro]m).

Caption: Figure 2. Correlation of CHD 9 expression and the prognosis of colorectal cancer.
Table 1. Correlation between clinical data and CHD 9 expression
in colorectal cancer.

                         Sample size
                                           CHD 9 carcinoma
Clinical                                     score (means
parameters             N   Total   Loss      [+ or -] SD)

Gender                       85     2
  Male                 43                 8.37 [+ or -] 1.92
  Female               42                 8.48 [+ or -] 1.70
Age                          81     6
  >60 years            66                 8.48 [+ or -] 1.79
  [less than or        15                 8.27 [+ or -] 1.98
  equal to] 60 years
Tumor size                   85     2
  >5cm                 40                 8.30 [+ or -] 1.47
  [less than or        45                 8.49 [+ or -] 2.05
  equal to] 5cm
Pathological grading         86     1
  I                    3                  6.67 [+ or -] 2.31
  II                   43                 8.70 [+ or -] 1.68
  III                  40                 8.25 [+ or -] 1.62
Tumor                        79     8
  T1-T2                8                  8.25 [+ or -] 1.98
  T3-T4                71                 8.54 [+ or -] 1.76
Node                         86     1
  N0                   55                 8.47 [+ or -] 1.92
  N1                   22                 8.55 [+ or -] 1.26
  N2                   9                  7.78 [+ or -] 2.11
Metastasis                   86     1
  M0                   84                 8.43 [+ or -] 1.81
  M1                   2                  8.00 [+ or -] 0.00
Clinical staging             85     2
  Stage I              8                  8.25 [+ or -] 1.98
  Stage II             46                 8.43 [+ or -] 1.88
  Stage III            29                 8.34 [+ or -] 1.61
  Stage IV             2                  8.00 [+ or -] 0.00

                         Test
Clinical               statistic
parameters               (t/F)       P

Gender
  Male                   -0.27     0.792
  Female
Age
  >60 years              -0.42     0.677
  [less than or
  equal to] 60 years
Tumor size
  >5cm                   0.48      0.631
  [less than or
  equal to] 5cm
Pathological grading
  I                      2.19      0.118
  II
  III
Tumor
  T1-T2                  -0.43     0.668
  T3-T4
Node
  N0                     0.65      0.525
  N1
  N2
Metastasis
  M0                     -0.33     0.740
  M1
Clinical staging
  Stage I                0.06      0.980
  Stage II
  Stage III
  Stage IV

Student's t-test or one-way ANOVA.

Table 2. Correlation analysis of CHD 9 expression and mismatch
repair genes.

                                          CHD9
                                       carcinoma      MLH1
Variables               Correlation      score      carcinoma

CHD 9 carcinoma score   [r.sub.s]        1.000       -0.076
                        P                             0.491
                        N                  86          84
MLH1 carcinoma          [r.sub.s]        -0.076       1.000
                        P                0.491
                        N                  84          88
MSH2 carcinoma          [r.sub.s]        0.232        0.569
                        P                0.036       <0.001
                        N                  82          84
MSH6 carcinoma          [r.sub.s]        0.113        0.468
                        P                0.301       <0.001
                        N                  86          88
PMS2 carcinoma          [r.sub.s]        0.154        0.437
                        P                0.163       <0.001
                        N                  83          86

                                         MSH2        MSH6
Variables               Correlation    carcinoma   carcinoma

CHD 9 carcinoma score   [r.sub.s]        0.232       0.113
                        P                0.036       0.301
                        N                 82          86
MLH1 carcinoma          [r.sub.s]        0.569       0.468
                        P               <0.001      <0.001
                        N                 84          88
MSH2 carcinoma          [r.sub.s]        1.000       0.676
                        P                           <0.001
                        N                 85          85
MSH6 carcinoma          [r.sub.s]        0.676       1.000
                        P               <0.001
                        N                 85          90
PMS2 carcinoma          [r.sub.s]        0.276       0.290
                        P                0.012       0.006
                        N                 83          87

                                         PMS2
Variables               Correlation    carcinoma

CHD 9 carcinoma score   [r.sub.s]        0.154
                        P                0.163
                        N                 83
MLH1 carcinoma          [r.sub.s]        0.437
                        P               <0.001
                        N                 86
MSH2 carcinoma          [r.sub.s]        0.276
                        P                0.012
                        N                 83
MSH6 carcinoma          [r.sub.s]        0.290
                        P                0.006
                        N                 87
PMS2 carcinoma          [r.sub.s]        1.000
                        P
                        N                 87

[r.sub.s]: spearman correlation coefficient; P: P value;
N: number of subjects.


Table 3. COX multivariate regression analysis of the independent
predictors of CHD 9 in colorectal cancer patients.

Variables                 B       SE     Wald    P value    HR

CHD 9 carcinoma score   -0.688   0.314   4.801    0.028    0.503
Node                     0.463   0.361   1.642    0.200    1.589
Metastasis               1.063   0.859   1.532    0.216    2.896
Clinical staging         0.267   0.399   0.449    0.503    1.306

SE: standard error; HR: hazard ratio.
COPYRIGHT 2018 Associacao Brasileira de Divulgacao Cientifica (ABDC)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Xu, Li; Peng, Hui; Huang, Xiao-Xu; Xia, Ya-Bin; Hu, Kai-Feng; Zhang, Zheng-Ming
Publication:Brazilian Journal of Medical and Biological Research
Article Type:Report
Date:Sep 1, 2018
Words:3048
Previous Article:Mechanistic effect of the human GJB6 gene and its mutations in HaCaT cell proliferation and apoptosis.
Next Article:NLRP3 inflammasome signaling as an early molecular response is negatively controlled by miR-186 in CFA-induced prosopalgia mice.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |